Related Experiment Video
Updated: May 25, 2026
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
WldS but not Nmnat1 protects dopaminergic neurites from MPP+ neurotoxicity
Jo Ann V Antenor-Dorsey1, Karen L O'Malley
1Department of Anatomy and Neurobiology, Washington University School of Medicine, Saint Louis, MO 63110, USA.
Background:
The WldS mouse mutant ("Wallerian degeneration-slow") delays axonal degeneration in a variety of disorders including in vivo models of Parkinson's disease. The mechanisms underlying WldS -mediated axonal protection are unclear, although many studies have attributed WldS neuroprotection to the NAD+-synthesizing Nmnat1 portion of the fusion protein. Here, we used dissociated dopaminergic cultures to test the hypothesis that catalytically active Nmnat1 protects dopaminergic neurons from toxin-mediated axonal injury.
Results:
Using mutant mice and lentiviral transduction of dopaminergic neurons, the present findings demonstrate that WldS but not Nmnat1, Nmnat3, or cytoplasmically-targeted Nmnat1 protects dopamine axons from the parkinsonian mimetic N-methyl-4-phenylpyridinium (MPP+). Moreover, NAD+ synthesis is not required since enzymatically-inactive WldS still protects. In addition, NAD+ by itself is axonally protective and together with WldS is additive in the MPP+ model.
Conclusions:
Our data suggest that NAD+ and WldS act through separate and possibly parallel mechanisms to protect dopamine axons. As MPP+ is thought to impair mitochondrial function, these results suggest that WldS might be involved in preserving mitochondrial health or maintaining cellular metabolism.
Insights
The Wallerian degeneration-slow (WldS) protein protects dopamine axons from Parkinson's-like injury, independent of its NAD+ synthesis activity. NAD+ also offers protection, suggesting separate protective mechanisms.
Area of Science:
- Neuroscience
- Molecular Biology
- Cell Biology
Background:
- The WldS mouse mutant delays axonal degeneration in Parkinson's disease models.
- WldS neuroprotection is often attributed to its NAD+-synthesizing Nmnat1 component.
- Mechanisms of WldS-mediated axonal protection remain largely unclear.
Purpose of the Study:
- To investigate if catalytically active Nmnat1 protects dopaminergic neurons from toxin-induced axonal injury.
- To elucidate the role of NAD+ synthesis in WldS-mediated neuroprotection.
- To determine the specific protective mechanisms of WldS in dopaminergic axons.
Main Methods:
- Utilized dissociated dopaminergic cultures.
- Employed mutant mice and lentiviral transduction.
- Tested protection against the Parkinson's-associated toxin N-methyl-4-phenylpyridinium (MPP+).
Main Results:
- WldS, but not Nmnat1, Nmnat3, or cytoplasmically-localized Nmnat1, protected dopamine axons from MPP+.
- Enzymatically inactive WldS retained protective capabilities, indicating NAD+ synthesis is not required.
- NAD+ alone conferred axonal protection, and its effect was additive with WldS.
Conclusions:
- WldS and NAD+ protect dopamine axons via distinct, potentially parallel pathways.
- WldS may preserve mitochondrial function or cellular metabolism, as MPP+ is known to impair mitochondria.
- Findings challenge the sole reliance on Nmnat1's catalytic activity for WldS neuroprotection.
